<DOC>
	<DOCNO>NCT01223456</DOCNO>
	<brief_summary>This post marketing surveillance study aim monitor safety efficacy ONGLYZA condition actual use patient diagnose diabetes mellitus type 2 prescribed ONGLYZA physician .</brief_summary>
	<brief_title>Safety Efficacy Study ONGLYZA ( Saxagliptin ) Under Conditions Actual Use</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Diagnosis Type 2 Diabetes Mellitus Prescribed Saxagliptin patient 's attending physician Known allergic serious adverse reaction Saxagliptin Pregnant breastfeeding patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Saxagliptin</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>clinical practice</keyword>
</DOC>